Method and composition for targeted delivery of therapeutic agents
AssigneeMemorial Sloan Kettering Cancer Center
InventorsMichael R. MCDEVITT, Simone ALIDORI, Nima AKHAVEIN, David A. SCHEINBERG
Life of this patent
Estimating the term…
Abstract
Functionalized single walled or multi-walled carbon nanotubes (f-CNTs) can be delivered into mammals to targeted organs, such as the kidney and the liver. These f-CNTs may be non-covalently linked or covalently linked to therapeutic agents. In particular, the application delivers carbon nanotube-therapeutic agent conjugates to a target organ, thereby preventing or reducing damages to the organ caused by other agents or procedure.
Claims22
A method for preventing or reducing kidney or liver injury in a subject, comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising (1) one or more therapeutic nucleic acids conjugated to functionalized carbon nanotubes (f-CNTs) and (2) a pharmaceutically acceptable carrier, wherein said one or more therapeutic nucleic acids inhibit expression of one or more genes selected from the group consisting of MMP-9, JNK, Epas1, Hif1an, Ac1, Fih1, Irp1, Egln1, Egln2, Egln3, PHD1, PHD2, PHD3, CTR1, CTR2, cFOS, FOS, cJUN, JUN, Fra1, Fra2, ATP, AP-1, MEP1A, MEP1B, VIM, p53, FASR, FASL, COL3A1, Kim-1 and C3 gene.
A pharmaceutical composition for preventing or reducing kidney and/or liver injury, comprising (1) one or more therapeutic RNAs conjugated to functionalized carbon nanotubes (f-CNTs) and (2) a pharmaceutically acceptable carrier, wherein the one or more RNA inhibit expression of one or more genes selected from the group consisting of MMP-9, JNK, Epas1, Hif1an, Ac1, Fih1, Irp1, Egln1, Egln2, Egln3, PHD1, PHD2, PHD3, CTR1, CTR2, cFOS, FOS, cJUN, JUN, Fra1, Fra2, ATP, AP-1, MEP1A, MEP1B, VIM, p53, FASR, FASL, COL3A1, Kim-1 and C3 gene.
A method for reducing acute kidney injury in a subject, comprising administering to the subject an effective amount of a pharmaceutical composition, comprising:
- (1) one or more siRNAs conjugated to functionalized single wall carbon nanotubes (f-SWCNTs);
- and (2) a pharmaceutically acceptable carrier, wherein the one or more siRNAs inhibit expression of one or more genes selected from the group consisting of MMP-9, JNK, Epas1, Hif1an, Ac1, Fih1, Irp1, Egln1, Egln2, Egln3, PHD1, PHD2, PHD3, CTR1, CTR2, cFOS, FOS, cJUN, JUN, Fra1, Fra2, ATP, AP-1, MEP1A, MEP1B, VIM, p53, FASR, FASL, COL3A1, Kim-1 and C3 gene.
Dependencies are inferred from the claim text.